Roche cobas KRAS Mutation Test
Roche Molecular Systems, Inc. · Decision date Nov 4, 2026
What did the FDA approve?
On 2026-11-04, FDA recorded an approval decision (APPR) for P140023/S034, a Special (Immediate Track) PMA supplement to Roche Molecular Systems, Inc. The supplement covers updates to hazard information in the product labeling for the cobas® DNA Sample Preparation Kit, which is a component of the cobas® KRAS Mutation Test, cobas® BRAF V600 Mutation Test, and cobas® EFGR Mutation Test, v2.0. The recorded reason is a labeling change affecting indications, instructions, shelf life or tradename.
This action concerns labeling for a shared sample-preparation component rather than a new approval of the broader test system. The device category is a somatic gene mutation detection system, with Pathology as the listed specialty and product code OWD. The source record does not include the revised hazard text, the specific labeling sections changed, or supporting documents, so the content and clinical effect of the update remain unknown.
The title field names the KRAS test, while the statement also lists BRAF and EFGR tests; the record does not explain that difference. No efficacy, safety or patient-selection conclusions follow from this labeling action.
FDA approval order statement
Approval for updates to the hazard information on the product labeling for cobas DNA Sample Preparation Kit, a component of cobas KRAS Mutation Test, cobas BRAF V600 Mutation Test, and cobas EFGR Mutation Test, v2.0.
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Pathology
- Decision date
- Nov 4, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P140023/S034
- Regulatory pathway
- PMA supplement
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- Decision code
- APPR
- Decision date
- Nov 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Somatic gene mutation detection system.
- Applicant
- Roche Molecular Systems, Inc.
- Product code
- OWD
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P140023. Subsequent supplements may change the device or its indications.
FDA decision timeline
P140023 · Original PMA
COBAS KRAS MUTATION TEST
P140023/S034 received
Application receipt date recorded by FDA.
P140023/S033 · Related supplement
cobas KRAS Mutation Test
P140023/S034 · FDA decision
Special (Immediate Track)
Timeline entries are records held by MedtechLedger for P140023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P140023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
COBAS KRAS MUTATION TESTP140023 | Roche Molecular Systems, Inc. | PMA approval | May 7, 2015 | FDA |
cobas KRAS Mutation TestP140023/S033 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Explore the linked device profile
Other records with product code OWD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Roche cobas BRAF V600 Mutation TestP110020/S046 | Roche Molecular Systems, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Roche cobas EGFR Mutation Test, v2.0P120019/S045 | Roche | PMA supplement | Nov 4, 2026 | FDA |
cobas BRAF V600 Mutation TestP110020/S045 | Roche Molecular Systems, Inc. | PMA supplement | Oct 27, 2026 | FDA |
cobas EGFR Mutation Test, v2.0P120019/S044 | Roche | PMA supplement | Oct 27, 2026 | FDA |
cobas EZH2 Mutation TestP200014/S012 | Roche Molecular System, Inc. | PMA supplement | Oct 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roche Molecular Systems, Inc.
- Headquarters
- Not reported
- Brand website
- roche.com
- FDA applicant address
- 4300 Hacienda Dr., Pleasanton, CA, 94588
Sources and methodology
- Original FDA record: P140023/S034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


